Navigation Links
Diabetes drug shows promise against multiple sclerosis
Date:5/26/2009

A drug currently FDA-approved for use in diabetes shows some protective effects in the brains of patients with relapsing remitting multiple sclerosis, researchers at the University of Illinois at Chicago College of Medicine report in a study currently available online in the Journal of Neuroimmunology.

In a small, double-blinded clinical trial, patients with relapsing remitting multiple sclerosis were assigned to take pioglitazone (a drug commercially known as Actos used to treat type-2 diabetes) or a placebo. Patients continued their normal course of therapy during the trial.

Standard neurological tests were done initially, as were MRI scans to provide baseline values for lesions typically seen in MS patients. The patients were evaluated every two months, and blood samples were taken. Repeat MRI scans were done after five months and again after one year.

Patients taking pioglitazone showed significantly less loss of gray matter over the course of the one-year trial than patients taking placebo. Of the 21 patients who finished the study, patients taking pioglitazone had no adverse reactions and, further, found taking pioglitazone, which is administered in an oral tablet, easy.

"This is very encouraging," said Douglas Feinstein, research professor of anesthesiology at UIC. "Gray matter in the brain is the part that is rich in neurons. These preliminary results suggest that the drug has important effects on neuronal survival."

Feinstein's lab has been interested in the class of drugs called thiazolidinediones, or TZDs. Several TZDs have been approved for use in the treatment of type-2 diabetes because of the drugs' effect on the body's response to insulin.

The researchers focused on pioglitazone because of its known anti-inflammatory effects, Feinstein said. They used primary cultures of brain cells to show that pioglitazone reduced the production of toxic chemicals called cytokines and reactive oxygen species. These molecules are believed to be important in the development of symptoms in MS.

Feinstein's lab proceeded to test pioglitazone in an animal model of MS. They and others showed that pioglitazone and other TZDs "can significantly reduce the clinical signs in mice with an MS-type disease," said Feinstein.

"More importantly, when mice who are already ill are treated with pioglitazone, the clinical signs of the disease go away," he said. "We were able to induce almost complete remissions in a number of mice."

"We are now working to determine the mechanisms to explain the protective effect on neurons that we see in our studies," said Feinstein. "We hope to expand into a larger trial to confirm these preliminary results."


'/>"/>

Contact: Jeanne Galatzer-Levy
jgala@uic.edu
312-996-1583
University of Illinois at Chicago
Source:Eurekalert

Related medicine news :

1. JDRF Illinois Names Allscripts CEO Glen Tullman Best of Illinois for His Efforts to Find a Cure for Type 1 Diabetes
2. Specialty care costs for patients with bipolar disorder are higher than diabetes and other chronic diseases
3. Specialty Care Costs for Patients With Bipolar Disorder Are Higher Than Diabetes and Other Chronic Diseases
4. Regulating the sugar factory in diabetes
5. Telemedicine may improve care for school children with diabetes
6. Americans Who Dont Know They Have Diabetes Incur $18 Billion in Health Expenses Each Year
7. Studies Reveal Exposure to Pesticides During Pregnancy Increases Risk of Premature Birth, Low-Birth Weight, Neurological Problems and Diabetes
8. The Launch and Uptake of More Than 20 Novel Drugs Over The Next 10 Years Will Drive $12.5 Billion Growth in the Type 2 Diabetes Market
9. New Report Shows Record Number of Medicines Currently in Development to Treat Diabetes
10. New Report Released in North Carolina Shows Record Number of Medicines in Development to Treat Diabetes
11. Lilly and Medtronic Form Alliance to Provide Solutions for Diabetes Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , ... May 25, 2016 , ... Stern Environmental ... will be selling the device branded as Stern’s Real Time Monitoring (RTM) ... bedbugs to the hotel and motel industry, colleges for use in dormitories, shelters, and ...
(Date:5/24/2016)... Milwaukee, WI (PRWEB) , ... May 24, 2016 ... ... has announced that Rudolfo (Rudy) Cifolelli has joined the company as Vice President ... and the development of U.S. and international sales in the rapidly expanding field ...
(Date:5/24/2016)... ... ... Jericho Project has named LaToya Williams-Belfort to the position of Chief Development and ... for the nationally-acclaimed nonprofit, working closely with CEO Tori Lyon and the Board of ... roots. , “LaToya Williams-Belfort is joining Jericho at an exciting time of growth ...
(Date:5/24/2016)... ... 2016 , ... How to Write Error Free Procedures, **Presented by Ginette M. ... error is known to be the major cause of quality and production losses in ... many human performance problems can be prevented. , How to Write Error Free Procedures, ...
(Date:5/24/2016)... ... , ... Loma Linda University Health (LLUH) has officially broken ground on the ... 3,000 people looked on as the shovels hit the dirt at the community groundbreaking ... During the program, Richard H. Hart, MD, DrPH, president, LLUH, recapped the history of ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... 23, 2016 The World Health Organization (WHO) expanded ... to include adolescents aged 13 years, and above. Effective immediately, ... for adult and adolescent males in the 14 priority countries ... was the first male circumcision device to receive WHO Prequalification ... Eddy Horowitz said: " The expanded use ...
(Date:5/23/2016)... 2016 Experts from various countries ... and the role of technology in innovative healthcare ... The First International Conference of VPS-Penn Medicine opened in ... presence of Sheikh Nahyan bin Mubarak Al Nahyan, Minister of ... which helps provide personalized medicine and tailor-made healthcare in disease ...
(Date:5/23/2016)... 2016 The global  reprocessed medical ... by 2022, according to a new study by Grand ... coupled with the lack of centralized support for waste ... the demand for reprocessed medical devices market. Additionally, the ... that of the original device is the high impact ...
Breaking Medicine Technology: